Transplant and GVHD from the 2025 Chapel Hill Patient and Family Conference
In this recording, Dr. Jeremy Meier discusses the journey of a transplant (before, during and after) and potential management of GVHD.
treatment
Aplastic Anemia from the 2025 Chapel Hill Patient and Family Conference
Cyclophosphamide and Cyclosporin for GVHD Prevention
Curtis et al. (July 17 issue)1 report evidence of longer graft-versus-host disease (GVHD)–free, relapse-free survival with post-transplantation cyclophosphamide–based prophylaxis than with cyclosporin–methotrexate among patients receiving a stem-cell transplant from a matched related donor after myeloablative conditioning or reduced-intensity conditioning.
Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms: A Systematic Review and Meta-Analysis
Luspatercept has emerged as a novel therapy for anemia in transfusion-dependent (TD) lower-risk
Azacitidine as therapy for VEXAS syndrome
How should patients with VEXAS (an acronym for vacuoles [in myeloid and erythroid precursors], E1 enzyme, X-linked, autoinflammatory, somatic) syndrome be treated? Until now, we have only had case reports and small series to guide us.
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
Abstract
What is Aplastic Anemia? From the 2025 Boston Patient and Family Conference
High Risk MDS from the 2025 Boston Patient and Family Conference
In this recording, Dr. Jacqueline Garcia discusses the diagnosis of high risk MDS and the treatment options available to patients.
MDS to MPN Overlap from the 2025 Boston Patient and Family Conference
In this recording, Dr. Richard Stone discusses the diagnosis of MDS/MPN overlap and the treatment options available to patients.
Low Risk MDS from the 2025 Boston Patient and Family Conference
In this recording, Dr. Andrew Brunner discusses the diagnosis of low risk MDS overlap and the treatment options available to patients.